Results 141 to 150 of about 339,354 (311)

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Age and gender disparities in oral anticoagulant use: a nine-year nationwide drug utilization analysis. [PDF]

Front Pharmacol
Omer AAA, Csatordai M, Viola R, Doró P.
europepmc   +1 more source

Drug Utilization Review Program Newsletter Drug Utilization Review Bulletin

, 2011
In 2009 this publication's title changed from Drug Utilization Review Bulletin to Drug Utilization Review Newsletter This internet resource contains several newsletters issued throughout several ...
Kansas. Department of Health and Environment
core  

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries. [PDF]

Ther Adv Neurol Disord
de Keijzer C, E JY, Yang Q, Gitonga R, Hiller D, Jurgensen S, Salloum N, Cunha-Santos J, Hoogewys-Cynober E, Vinet L, Chirieac M, Benzerdjeb H, Thoene D, Ziemssen T, Drahota J, Horáková D, Brown W, Hobart J, Robertson NP, Hakkarainen KM, Sinnott SJ.   +20 more
europepmc   +1 more source

Drug Utilization Review Program Newsletter Drug Utilization Review Bulletin

, 2010
In 2009 this publication's title changed from Drug Utilization Review Bulletin to Drug Utilization Review Newsletter This internet resource contains several newsletters issued throughout several ...
Kansas. Department of Health and Environment
core  

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Trends in antipsychotic and lithium use in Scandinavian countries from 2010 to 2023: a cross-country drug utilization study. [PDF]

BMC Psychiatry
Hakimi NH, Larsen MD, Bojanic I.
europepmc   +1 more source

Drug Utilization Review Program Newsletter Drug Utilization Review Bulletin

, 2012
In 2009 this publication's title changed from Drug Utilization Review Bulletin to Drug Utilization Review Newsletter This internet resource contains several newsletters issued throughout several ...
Kansas. Department of Health and Environment
core  

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source